These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 15958593)

  • 1. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
    Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
    Long BJ; Jelovac D; Handratta V; Thiantanawat A; MacPherson N; Ragaz J; Goloubeva OG; Brodie AM
    J Natl Cancer Inst; 2004 Mar; 96(6):456-65. PubMed ID: 15026471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
    Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
    Macedo LF; Sabnis GJ; Goloubeva OG; Brodie A
    Cancer Res; 2008 May; 68(9):3516-22. PubMed ID: 18451180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
    Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic observations in MCF-7 aromatase xenografts.
    Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
    Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
    Smollich M; Götte M; Fischgräbe J; Macedo LF; Brodie A; Chen S; Radke I; Kiesel L; Wülfing P
    Breast Cancer Res Treat; 2010 Sep; 123(2):345-57. PubMed ID: 19943105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
    Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
    Brodie AH; Jelovac D; Long B
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
    Belosay A; Brodie AM; Njar VC
    Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
    Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
    Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
    Brodie A; Jelovac D; Long BJ
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
    Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xenograft models for aromatase inhibitor studies.
    Brodie A; Sabnis G; Macedo L
    J Steroid Biochem Mol Biol; 2007; 106(1-5):119-24. PubMed ID: 17611101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
    Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
    Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.